Mr Simon Brewster

Qualifications

BSc (1st class Hons. Anatomy, Lon), MD (Bristol), FRCS (Urol)

GMC number: 3169148

Practising since: 1986

Specialties

Urology

Consultation times

  • Tuesday by arrangement
  • Overview
Book online today Enquire now

Or call us on

01865 307445

About

Simon Brewster specialises in prostate cancer and other prostate disease (PSA kinetics, benign prostatic hyperplasia (BPH), prostatitis). He is trained as a general urologist and treats a variety of conditions including blood in the urine (haematuria), bladder cancer and recurrent urinary infections. Simon finished his basic medical training at Charing Cross Hospital in 1986, graduating with honours in Pathology and a 1st class BSc degree in Anatomy. He worked as an anatomy demonstrator at his medical school for a year before moving to Bristol to train in Urology.

During this time he developed his interest in prostate disease, having spent two years in full-time laboratory research, leading to the award of his MD doctorate thesis in 1993 from Bristol University. During the final stages of his training he attained the FRCS (Urology) and went to John Hopkins Hospital, Baltimore to develop expertise in radical prostatectomy with Dr Patrick Walsh. He was appointed as a consultant and honorary senior lecturer in Oxford in 1998, where he pioneered the prostate cancer diagnostic and active surveillance services, radical prostatectomy, transperineal prostate biopsy and Holmium laser prostate enucleation (HoLEP). He currently sits on the Board of Governors and leads on undergraduate teaching and clinical governance for the urology department of Oxford University Hospitals NHS Foundation Trust. New procedures he can offer include SpaceOAR gel implant and Rezum convective ablation of the prostate.

Contact

PA email : kate.taylor@nuffieldhealth.com
Website: www.topdoctors.co.uk/doctor/simon-frederick-brewster 

Personal interests

Simon is married to a GP and they have two teenage daughters. He enjoys sports including running and triathlon. He also enjoys listening to music and watching ballet.

Treatments and tests offered by Mr Simon Brewster at Nuffield Health

  • Holmium laser enucleation of the prostate (HoLEP)
  • SpaceOAR® Hydrogel
  • Testicular ultrasound
  • Transurethral resection of bladder tumour (TURBT)
  • Prostate surgery
  • Prostate screening
  • Cystoscopy
  • Prostate resection (TURP)
  • Orchidectomy
  • Circumcision
  • Rezum for benign prostatic hyperplasia
  • Penile lesions (biopsy of)

Locations Mr Simon Brewster works with

Related experience

Research

Since qualifying as a doctor, Simon has authored 89 peer-reviewed papers and two textbooks, including the successful Oxford Handbook of Urology, now in its 4th edition (Oxford Univ. Press). His MD thesis was written about molecular genetic abnormalities in prostate cancer.

He contributes to clinical trials, currently including a randomised trial of focal therapy versus radical prostatectomy for prostate cancer. He is a Fellow of Hertford College (Oxford University) where he provides its medical students with clinical teaching and pastoral support.

Simon contributes to the content of several patient information booklets and webpages produced by Prostate Cancer UK and helped to found the Oxfordshire Prostate Cancer Support Group in 2010. 
Simon Brewster: PUBLICATIONS IN JOURNALS 

1. THE DEVELOPMENT AND DIFFERENTIATION OF HUMAN SEMINAL VESICLES SF Brewster Journal of Anatomy 1985; 143: 45 - 55.

2. THE DEVELOPMENT OF THE LIGAMENT OF THE HEAD OF THE FEMUR SF Brewster Clinical Anatomy 1990; 4: 245 - 255.

3. A MALE PSEUDOHERMAPHRODITE WITH NOONAN’S SYNDROME SF Brewster, RM Kennedy, PJB Smith British Journal of Urology 1992;  67: 96 - 97.

4.THE VARICOSE VEIN WAITING LIST - RESULTS OF A VALIDATION EXERCISE SF Brewster, S Nicholson, JR Farndon Annals of the Royal College of Surgeons 1991; 73: 223 - 226.

5. CAN KNEE REPLACEMENTS BE ASSESSED BY POST? SF Brewster, JH Newman Health Trends  1991;  23: 113 - 114.

6. INTRA-VESICAL FOREIGN BODIES - A FIVE-YEAR REVIEW SD Eckford, RA Persad, SF Brewster, JC Gingell British Journal of Urology  1992;  69: 41 - 45. 

7. TUMOUR SUPPRESSOR GENES IN URINARY TRACT ONCOLOGY - A REVIEW SF Brewster, JC Gingell, KW Brown British Journal of Urology  1992;  70: 585 - 590. 

8. TRANSRECTAL BIOPSY - RESULTS OF ANTIMICROBIAL PROPHYLAXIS QUESTIONNAIRE SF Brewster British Journal of Urology  1992;  70: 596.

9. ADVANCED PROSTATE CANCER - WHAT’S NEW IN HORMONAL MANIPULATION? SF Brewster and DA Gillatt British Journal of Hospital Medicine   1993;   49 :  710-715. 

10. A FATAL ANAEROBIC SEPSIS FOLLOWING TRANSRECTAL BIOPSY OF A RARE PROSTATIC TUMOUR SF Brewster, N Rooney, J Kabala, RCL Feneley British Journal of Urology  1993;  77 : 977 - 978. 

11. GENE THERAPY FOR CANCER: WHAT’S IT ALL ABOUT? SF Brewster Hospital Update 1994 ;   20 : 140 - 150.

12. SOMATIC ALLELIC LOSSES AT TUMOUR SUPPRESSOR GENES DCC, p53, nm23-HI AND APC LOCI IN HUMAN PROSTATIC CARCINOMA SF Brewster, S Browne, KW Brown Journal of Urology  1994 ;  151:  1073 - 1077. 

13. PELVIC APPENDICITIS IN YOUNG MALES MASQUERADING AS CYSTITIS SF Brewster, A Lovering, J McLoughlin Journal of the Royal College of Surgeons of Edinburgh  1994;  39:  119 - 120.

14. GENE THERAPY IN UROLOGICAL ONCOLOGY : PRINCIPLES, STRATEGIES AND POTENTIAL SF Brewster and JW Simons European Urology,   1994;  25:  177 - 182. 

15. THE ACUTE SURGICAL ADMISSION: IS MORTALITY PREDICTABLE IN THE ELDERLY? RH Kennedy, AM Al-Mufti, SF Brewster, EN Sherry, TR Magee, TT Irvin. Annals of the Royal College of Surgeons 1994; 76: 342 - 345.

16. SCREENING FOR PROSTATE CANCER IN GENERAL PRACTICE  - RESULTS OF A 3-YEAR FOLLOW-UP SF Brewster, T Kemple, A MacIver, P Astley and JC Gingell British Journal of Urology 1994; 74: 556 - 558.

17. LOSS OF HETEROZYGOSITY ON CHROMOSOME 18q  IS ASSOCIATED WITH MUSCLE-INVASIVE TRANSITIONAL CELL CARCINOMA OF THE BLADDER SF Brewster, JC Gingell and KW Brown British Journal of Cancer 1994; 70: 697-700.

18. THE ROLE OF CANCER GENES IN THE DEVELOPMENT OF PROSTATE CANCER SF Brewster Endocrine-related Cancer 1994; 3: 27 - 39. 

19. THE PROSPECTS OF GENE THERAPY FOR UROLOGICAL MALIGNANCY SF Brewster Current Medical Literature: Urology 1995; 1: 31 - 36. 

20. Antimicrobial prophylaxis for transrectal biopsy of the prostate: a prospective randomised trial.SF Brewster, AG MacGowan & JC Gingell British Journal of Urology 1995; 76: 351-354.

21. Reply to letter commenting on  “Antimicrobial prophylaxis for transrectal biopsy of the prostate: a prospective randomised trial” SF Brewster, AG MacGowan & JC Gingell. British Journal of Urology 1995; 76: 351-354. British Journal of Urology 1996; 77: 618-619. 

22. The tumour suppressor gene nm23-H1 in bladder cancer SF Brewster & JC Gingell British Journal of Urology 1996; 78: 321-322(letter). 

23.PROBLEMS IN DIAGNOSIS AND MANAGEMENT OF GOITRE IN CHILDHOOD AND ADOLESCENCE. AJ Webb, SF Brewster & D Newington British Jourmal of Surgery 1996; 83: 1586-1590.

24. Antimicrobial prophylaxis for prostatic biopsy SF Brewster Current Opinion in Urology 1997; 7: 57-60. 

25. INACTIVATION OF THE RETINOBLASTOMA SUSCEPTIBILITY GENE (RB1) IN EYE AND BLADDER TUMOURS FROM THE SAME PATIENT SF Brewster, Margaret Knowles, David Poller and  J Gingell British Journal of Urology, 1998; 81: 494-495.

26. P53, BCL-2, CD44 AND E-CADHERIN AS PREOPERATIVE PREDICTORS OF TREATMENT FAILURE AFTER RADICAL PROSTATECTOMY. SF Brewster, Jon Oxley, Clive Abbott and David A Gillatt Jounal of Urology, 1999; 161: 1238-1243.

27. UROLOGY AND THE INTERNET: AN EVALUATION OF INTERNET USE BY UROLOGY PATIENTS AND OF INFORMATION AVAILABLE ON UROLOGICAL TOPICS. G.O. Hellawell, KJ Turner, KJ Le Monnier and SF Brewster British Journal of Urology, 2000; 86: 191-194. 

28. UP-REGULATION AND ALTERED DISTRIBUTION OF IGF-1 RECEPTOR IN HUMAN PROSTATE CANCER. G.O. Hellawell, D.R. Davies, H. Turley, SF Brewster and V.M. Macaulay British Journal of Urology, 2000; 86: 360-393.

29. DIGITAL RECTAL EXAMINATION BY MEDICAL STUDENTS AND HOUSE OFFICERS. TAUGHT, NOT DONE. K.J Turner and S.F. Brewster Prostate Cancer and Prostatic Diseases, 2000; 3, 128-129.

30. RANDOMISED TRIALS IN EARLY PROSTATE CANCER II: HORMONE THERAPY AND RADIOTHERAPY FOR LOCALLY-ADVANCED DISEASE: A QUESTION STILL UNANSWERED. MJ Mason, S Brewster, LE Moffat, P Kirkbride, RA Cowan, P Malone, M Sydes, & MK Parmer Clinical Oncology, 2000; 12: 215-216.

31. THE ATTITUDES AND USES OF ALTERNATIVE THERAPIES BY UK PROSTATE CANCER PATIENTS – ISN’T IT TIME WE WERE IN THE KNOW?. P Cheetham, K LeMonnier & SF Brewster Prostate Cancer and Prostatic Diseases, 2001; 4, 235-241. 

32. p53 and bcl-2 IMMUNOHISTOCHEMISTRY IN PREOPERATIVE BIOPSIES AS PREDICTORS OF BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY  JD Oxley, MH Winkler, K Parry, SF Brewster, C Abbott & DA Gillatt BJU International, 2002; 89, 27-32.

33. GROWTH FACTORS AND THEIR RECEPTORS IN PROSTATE CANCER GO Hellawell & SF Brewster BJU International, 2002; 89, 230-240. 

34. Prostate Cancer SF Brewster J Ass Ch Phys Wom Health 2002; 90, 17-18.

35. CAN SAW PALMETTO HELP IN PROSTATE CANCER? SF Brewster Pulse 2002; 62, 60. 

36. Screening for prostate cancer in the UK J Ord & SF Brewster BMJ Rapid Response 18/04/2002 http://www.bmj.com/cgi/eletters/323/7316/763 

37. EXPRESSION OF THE TYPE 1 INSULIN-LIKE GROWTH FACTOR RECEPTOR IS UP-REGULATED IN PRIMARY PROSTATE CANCER AND COMMONLY PERSISTS IN METASTATIC DISEASE GO Hellawell, GH Turner, DR Davies, R Poulsom , SF Brewster & VM Macaulay Cancer Research 2002; 62, 2942-2950. 

38. BMJ USA : Letter SF Brewster, M Feneley & R Kirby BMJ Rapid Response 4/10/2002 http://www.bmj.com/cgigi/content/full/bmj%3B327/7418/E177 

39. OPPORTUNITIES AND OUTCOMES IN EARLY PROSTATE CANCER: A COMMENTARY ON POLICY, PATIENT PERSPECTIVES, TRIALS AND STRATEGIES M.R. Feneley & S. Brewster BJU International 2003; 91, 177-178. 

40. CHEMOSENSITISATION OF HUMAN PROSTATE CANCER USING ANTISENSE AGENTS TARGETING THE TYPE-1 INSULIN-LIKE GROWTH FACTOR RECEPTOR GO Hellawell, D.J.P. Ferguson, SF Brewster & VM Macaulay BJU International 2003; 91, 271-277. 

41. THE USE OF ASPIRIN WITH PC-SPES MAY NOT PREVENT PULMONARY EMBOLISM SM Biers & SF Brewster BJU International 2003; 91, 428.

42. Editorial Comment on BIOCHEMICAL DISEASE-FREE SURVIVAL IN PATIENTS WITH A HIGH PSA AND CLINICALLY-LOCALIZED PROSTATE CANCER AFTER RADICAL PROSTATECTOMY by Brandli DW et al. BJU International 2003; 92, 19-22. SF Brewster BJU International 2003; 92, 22-23. 

43. THE TYPE 1 INSULIN-LIKE GROWTH FACTOR RECEPTOR IS OVER-EXPRESSED IN BLADDER CANCER, AND TARGETING BY RNA INTERFERENCE REDUCES IN VITRO SURVIVAL. Rochester MA, Patel N, Hellawell GO, Brewster SF & Macaulay VM. J Urol 2004: 171, S195.

44. GENETICS FOR UROLOGISTS. Rochester MA, & Brewster SF. BJUI EBU Update 2004: 94, 232.

45. A double-blind, randomized, controlled trial of topical glyceryltrinitrate for transrectal     ultrasound guided prostate biopsy. Rochester MA, Le Monnier K, Brewster SF. J Urol. 2005: 173(2):418-20.

46. SIlencing of the IGF1R gene enhances sensitivity to DNA-damaging agents in both PTEN wild- type and mutant human prostate cancer. Rochester MA, Riedemann J, Hellawell GO, Brewster SF, Macaulay VM. Cancer Gene Ther. 2005: 12(1): 90-100.

47. LONG-TERM OUTCOMES AND MORBIDITY AFTER I125 BRACHYTHERAPY FOR LOCALISED PROSTATE CANCER: AN EARLY UK SERIES. Hellawell GO, Le Monnier K,Davies D, Fellows GJ, Whipp E and Brewster SF. Clinical Oncology 2005: 17, 68. 

48. Wnt SIGNALLING and PROSTATE CANCER. Yardy GW & Brewster SF. Prostate Cancer & Prostatic Diseases 2005: 8, 119-126. 

49. The Wnt signaling pathway is a potential therapeutic target in prostate cancer. Yardy GW & Brewster SF. BJU International 2006; 98, 719-21. 

50. Are 2 repeat prostate biopsies sufficient to determine the outcome of High-Grade PIN and ASAP on initial prostate biopsy? W.C. Tsang, I.S.D Roberts and S. Brewster. Eur Urol  2007: 6, 123.

51. High-intensity focussed ultrasound for localised prostate cancer: intra-operative determinants of biopsy-proven failure using the Sonablate 500 system. Calleary J, Leslie T, Illing R, Kennedy J, Brewster S, Allen C, Emberton M. Eur Urol  2007: 6, 123. 

52. Patients’ perceptions of transrectal prostate biopsy: a qualitative study. Chapple AB, Ziebland S, Brewster S & Mcpherson A. Eur J Cancer 2007: 16, 215-221. 

53. A RANDOMISED CONTROLLED TRIAL OF TOPICAL GTN BEFORE TRUS-GUIDED BIOPSY (letter).  Brewster S & Rochester M. BJU International 2007: 100, 1412-1413.

54. Single focus prostate cancer on TRUS biopsy – Does size matter? Tsang WC, Kaur J, Robert I and Brewster S. Eur Urol 2008: 7, 274. 

55. NICE GUIDANCE ON PROSTATE CANCER AND THE ROLE OF ACTIVE SURVEILLANCE FOR LOW-RISK, LOCALISED DISEASE. Marsh HP & Brewster SF. BMJ Rapid Response March 2008. http://www.bmj.com/cgi/eletters/336/7644/610#192523

56. LOW-RISK LOCALISED PROSTATE CANCER: ARE WE READY TO RECOMMEND ACTIVE SURVEILLANCE AS THE PREFERRED OPTION? Brewster SF. BJUI 2008: 102, 923-926. 

57. MUTATIONS IN THE AXIN1 GENE IN ADVANCED PROSTATE CANCER Yardy GW, Bicknel DC, Wilding JL, Bartlett S, Lui Y, Winney B, Turner G, Brewster SF & Bodmer WF. Eur Urol 2009: 56; 486-494.

58. High-intensity focused ultrasound for localised prostate cancer: initial experience with a 2- year follow-up. Leslie T & Brewster S. BJUI 2010: 105, 726-727. 

59. Challenging the EAU 2009 Guidelines on Testis Cancer: The Risk-Adapted Management of Stage I Nonseminomatous Germ Cell Tumours: Surveillance Yields Equal Results With Less Toxicity. Brewster SF. Eur Urol Supps. 2010: 9; 459-461.

60. FOCAL THERAPY FOR PROSTATE CANCER; POSSIBILITIES AND LIMITATIONS. Eggener S, Salomon G, Scardino, PT, De la Rosette J, Polascik TJ, Brewster S. Eur Urol 2010: 58; 57-64. 

61. Does the presence of robotic surgery affect demographics in patients choosing to undergo radical prostatectomy? A multi-center contemporary analysis. Philippa J. Cheetham, Daniel J. Lee, Anna Rose-Morris, Simon F. Brewster, Ketan Badani. J Robotic Surgery 2010.

62. PROSPECTIVE STUDY OF CURRENT PROSTATE BIOPSY PRACTICES AMONG ONCOLOGICAL UROLOGISTS Brewster S, Turkeri L, Brausi M, Ravery V, Djavan B. anadian J Urol 2010: 17; 5071-5076.

63. Serial analysis of resected prostate cancer suggests up-Regulation of type 1 IGF receptor with disease progression. Turney B W, Turner GDH, Brewster SF & Macaulay V. BJUI 2011: 107; 1488-1499.

64. Testicular Torsion: A painful turn of events. Kirthi, V & Brewster S. Student BMJ 2011: 19; 26-27. 

65. Focal therapy is an option for the majority of localised prostate cancers: histopathological study of contemporary UK radical prostatectomies Aslam MA, Turner, G, Brewster SF. Br J MSU 2011: 4; 166-170.

66. Prostate cancer: to screen or not to screen. Bailey SJV & Brewster SF. Arch. Esp. Urol. 2011: 64 (5); 406-418.

67. EXAMINATION OF THE MALE GENITALIA Kirthi V., Ellis B. & Brewster S. Journal of Clinical Examination 2011: 11; 22-31. 

68. The Digital rectal examination Shirley A & Brewster SF. Journal of Clinical Examination 2011: 11; 1-12. 

69. PSA KINETICS IN THE DIAGNOSIS AND MANAGEMENT OF PROSTATE CANCER Vickers A & Brewster SF. British Journal of Medical and Surgical Urology 2012: 5; 162-168

70. Müllerianosis: a rare cause of acute renal colic. Ndokera R, Brewster SF & Dhar S BMJ Case Reports 2012; doi:10.1136/bcr-2012-006704 

71. Glove at first sight – History of the first surgical rubber glove. Bhatt JR, Wood IRG, Hobbs CP, Brewster S. Eur Urol 2013; 12(1) Supp 1077 

72. CONTEMPORARY PRACTICE AND TECHNIQUE RELATED OUTCOMES FOR RADICAL PROSTATECTOMY IN THE UNITED KINGDOM: A REPORT OF NATIONAL OUTCOMES. Laird A, Fowler S, Good S, Stewart G, Srinivasan, Cahill, Brewster SF, McNeill A. on behalf of BAUS Section of Oncology. BJUI 2015: 115: 753-763. 

73. NICE GUIDELINES ON PROSTATE CANCER ACTIVE SURVEILLANCE: IS UK PRACTICE LEADING THE WORLD? Streeter E & Brewster SF. BJUI 2015: 115; 12-13. 

74. IMPROVING THE DIAGNOSIS AND TREATMENT OF HIGH-RISK LOCALISED OR LOCALLY ADVANCED PROSTATE CANCER IN THE UK Payne H, Khoo V, Clarke N, Beresford M, Moore C, AslettP, Bahl A, Bhatt R, Greg Boustead G, Brewster S & Kirby R. Health Trends 2015: 6; 26-30. 

75. IMPROVING THE SURGICAL TREATMENT OF HIGH-RISK LOCALISED OR LOCALLY ADVANCED PROSTATE CANCER IN THE UK Kirby R, Payne H, Khoo V, Clarke N, Beresford M, Moore C, AslettP, Bahl A, Bhatt R, Greg Boustead G &Brewster S. Health Trends 2015: 6; 29-32. 

76. VARIATION BETWEEN SPECIALIST UROPATHOLGISTS IN REPORTING EXTRAPROSTATIC EXTENSION AFTER RADICAL PROSTATECTOMY. Bryant RJ, Schmitt AJ, Roberts ID, Gill S P,Browning L, Brewster SF, Hamdy FC, Verrill CJ. J Clin Pathol 2015; 68: 465–472. 

77. ESTABLISHING NURSE-LED ACTIVE SURVEILLANCE FOR MEN WITH LOCALISED PROSTATE CANCER: DEVELOPMENT AND FORMATIVE EVALUATION OF A MODEL OF CARE IN THE PROTECT TRIAL. Julia Wade, Peter N Holding, Susan Bonnington, Leila Rooshenas, J Athene Lane, C Elizabeth Salter, Kate Tilling, Mark J Speakman, Simon F Brewster, Simon Evans, David E Neal, Freddie C Hamdy, Jenny L Donovan For The Protect Study Group. BMJ Open 2015;5:e008953.doi:10.1136/bmjopen-2015-008953 22 Sept 2015

78. UROLOGICAL RECOMMENDATIONS FROM THE NICE GUIDELINE, JUNE 2015: SUSPECTED CANCER: RECOGNITION AND REFERRAL Jefferies ER & Brewster SF on behalf of the BAUS Section of Oncology. BJUI 2015 epub ahead of publication; doi: 10.1111/bju13355. 

79. ALTERED EXPRESSION OF MARKERS OF EPITHELIAL-TO-MESENCHYMAL TRANSITION AT THE EXTRAPROSTATIC EXTENSION COMPONENT OF LOCALLY INVASIVE PROSTATE CANCERS. Bryant RJ, Schmitt AJ, Roberts ID, Gill S P,Browning L, Brewster SF, Hamdy FC, Verrill C. J.. Submitted to Oncotarget 2015. 

80. PROSTATE BIOPSY – WHAT IS THE MOST APPROPRIATE APPROACH? Richard Bryant & Simon Brewster. BJUI Knowledge 2016 https://app.tessello.co.uk/CourseStore/clients/BJUI/71712  Prostatebiopsywhatistheappropr-2016113141647/launch.html  doi: 10.18591/BJUIK.0184 

81. ADVANCES IN UROLOGY 2015-2016. Brewster S, Biers S, Challacombe B, Cresswell J, Sinclair A & Smith D. J Clin Urol 2017; 10: 39-48.

82. INTRODUCING MPMRI INTO CONTEMPORARY UK ACTIVE SURVEILLANCE FOR LOCALISED PROSTATE CANCER. Bryant Rj, Yang B, Philippou Y, Lam K, Obiakor M, Ayers J, Gleeson F, Macpherson R, Verrill C, Roberts I, Leslie T, Crew J, Sooriakumaran P, Hamdy Fc, Brewster S. J Urol 2017;197:No. 4S, e1054.

83. MANAGING PATIENTS WITH METASTATIC PROSTATE CANCER: WHO TAKES THE LEAD? Hughes, S, McNeill A, Brewster S, Clarke N, Troup J & Payne H. Health Trends 2017; 8: 25-30.
84. REDUCING MORTALITY IN THE AGEING PATIENT: TREATMENT OF THE PRIMARY TUMOUR IS NOT NECESSARY. Lamb AD, Brewster SF, Hamdy FC. European Urology Focus 2018; 3, 328-329.
85. HIGH LEVELS OF PATIENT SATISFACTION IN JOINT URO-ONCOLOGY CLINICS TO ASSIST PATIENT CHOICE IN EARLY PROSTATE CANCER AND MUSCLE- NVSIVE BLADDER CANCER. Kiltie AE, Southby R, LeMonnier K, Binnee J, Niederer J, Kartsonaki C, Camilleri P, Sabharwal A, Brewster S, Crew J, Hamdy FC. Clin Oncol (R Coll Radiol). 2018; 30; e39.

86. DOES THE INTRODUCTION OF PROSTATE MULTIPARAMETRIC MRI INTO ACTIVE SURVEILLANCE OF LOCALISED PROSTATE CANCER IMPROVE PATIENT RE‐CLASSIFICATION? RJ Bryant B Yang, Y Philippou K Lam M Obiakor J Ayers V Chiocchia F Gleeson R MacPherson C VerrillP Sooriakumaran FC Hamdy & SF Brewster BJUI 2018 ; 122 : 794-800. (Awarded “Article of the Week” by the editor, 18/11/18)

87. EFFECTS OF INTRODUCING PRE-BIOPSY MPMRI INTO CONTEMPORARY UK PROSTATE CANCER DETECTION. C. Hobbs, Hamdy FC, Brewster SF, Bryant R European Urology Supplements 2018 17(2):e1870. 

88. OVERCOMING DIFFICULTIES WITH EQUIPOISE TO ENABLE RECRUITMENT TO A RANDOMISED TRIAL OF PARTIAL ABLATION VS RADICAL PROSTATECTOMY FOR UNILATERAL LOCALISED PROSTATE CANCER. Elliott D, Hamdy FC, Leslie T, Rosario D, Dudderidge T, Hindley R, Emberton M, Brewster S, Sooriakumaran P, Catto J, Emara A, Ahmed H, Whybrow P, lc Conte S, Donovan J. BJUI 2018; 122: 970-7. 

89. COMPARISON OF PROSTATE BIOPSY WITH OR WITHOUT PRE-BIOPSY MPMRI FOR PROSTATE CANCER DETECTION: AN OBSERVATIONAL COHORT STUDY Bryant RJ , Hobbs CP, Eyre KS, Davies LC, McCormick R, Sullivan ME, Shields W, Verrill C, Gleeson F, MacPherson R, Hamdy FC , Brewster SF. J Urol 2019; 201: 510-519. It includes an Editorial Comment and Reply by the authors.

90. 90. MORE MEN DIE WITH PROSTATE CANCER THAN BECAUSE OF IT - AN OLD ADAGE THAT STILL HOLDS TRUE IN THE 21ST CENTURY. Jacklin C, Philippou Y, Brewster SF & Bryant RJ. Cancer Treatment and Research Communications  2021; 26: 1-9. Doi.org/10.1016/j.ctarc.2020.100225.

Memberships

  • European Association of Urology
  • British Association of Urological Surgeons

Other posts held

  • Consultant Urological Surgeon, Churchill Hospital

Insurers Mr Simon Brewster works with

Mr Simon Brewster works with the following private medical insurance providers:

  • Aviva Health
  • AXA Health
  • Benenden Health
  • Bupa
  • Cigna
  • CS Healthcare
  • Exeter Family Friendly
  • Health-on-Line
  • PHC
  • Simplyhealth
  • WPA

Declaration

Mr Simon Brewster does not hold a share or financial interest in this hospital, another Nuffield Health hospital or the company.

Mr Simon Brewster does not have a share or financial interest in equipment used at this hospital or another Nuffield Health hospital.

Mr Simon Brewster does not hold any paid advisory role(s) at this hospital or on behalf of Nuffield Health.